Literature DB >> 1648718

Ablation of recurrent primary liver cancer using 131I-lipiodol.

R Novell1, A Hilson, K Hobbs.   

Abstract

A case of recurrent hepatocellular carcinoma following resection is reported. The patient received 2 treatments of 131I-lipiodol administered via the hepatic artery at angiography. Good localization in tumour tissue was observed on subsequent computed tomographic scans and no adverse effects were seen after either treatment. After the first treatment 2 nodules of recurrent tumour were resected and proved to be totally necrotic. The patient remains well 9 months later with a persistently elevated serum alphafetoprotein but no evidence of residual tumour. It is suggested that 131I-lipiodol may be the treatment of choice for small tumours in elderly high-risk patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648718      PMCID: PMC2398799          DOI: 10.1136/pgmj.67.786.393

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  12 in total

1.  Metastatic nodules of hepatocellular carcinoma: detection with angiography, CT, and US.

Authors:  N Hayashi; K Yamamoto; N Tamaki; T Shibata; K Itoh; I Fujisawa; Y Nakano; Y Yamaoka; N Kobayashi; K Mori
Journal:  Radiology       Date:  1987-10       Impact factor: 11.105

2.  Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents.

Authors:  K Takayasu; Y Shima; Y Muramatsu; N Moriyama; T Yamada; M Makuuchi; H Hasegawa; S Hirohashi
Journal:  Radiology       Date:  1987-05       Impact factor: 11.105

3.  Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents.

Authors:  H Ohishi; H Uchida; H Yoshimura; S Ohue; J Ueda; M Katsuragi; N Matsuo; Y Hosogi
Journal:  Radiology       Date:  1985-01       Impact factor: 11.105

4.  Elevation of alpha-fetoprotein level without evidence of recurrence after hepatectomy for hepatocellular carcinoma.

Authors:  T Ezaki; H Yukaya; Y Ogawa; Y C Chang; N Nagasue
Journal:  Cancer       Date:  1988-05-01       Impact factor: 6.860

5.  Primary hepatocellular carcinoma--etiology, pathogenesis, and prevention.

Authors:  W T London
Journal:  Hum Pathol       Date:  1981-12       Impact factor: 3.466

6.  Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer.

Authors:  M Nakajo; H Kobayashi; K Shimabukuro; K Shirono; H Sakata; M Taguchi; N Uchiyama; T Sonoda; S Shinohara
Journal:  J Nucl Med       Date:  1988-06       Impact factor: 10.057

7.  Dosimetry of iodine-131 ethiodol in the treatment of hepatoma.

Authors:  M T Madsen; C H Park; M L Thakur
Journal:  J Nucl Med       Date:  1988-06       Impact factor: 10.057

8.  Resectability rate of hepatocellular carcinoma in rural southern Africans.

Authors:  R Maraj; M C Kew; R J Hyslop
Journal:  Br J Surg       Date:  1988-04       Impact factor: 6.939

9.  Hepatic artery injection of I-131-labeled lipiodol. Part II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases.

Authors:  J F Bretagne; J L Raoul; P Bourguet; R Duvauferrier; Y Deugnier; R Faroux; A Ramée; J Y Herry; J Gastard
Journal:  Radiology       Date:  1988-08       Impact factor: 11.105

10.  Morbidity and mortality after major hepatic resection in cirrhotic patients with hepatocellular carcinoma.

Authors:  N Nagasue; H Yukaya; H Kohno; Y C Chang; T Nakamura
Journal:  HPB Surg       Date:  1988-09
View more
  1 in total

1.  In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines.

Authors:  R A Al-Mufti; R B Pedley; D Marshall; R H Begent; A Hilson; M C Winslet; K E Hobbs
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.